• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: propensity score-handle with care.

作者信息

Macaluso Fabio Salvatore, Orlando Ambrogio

机构信息

IBD Unit, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy.

出版信息

Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179.

DOI:10.1111/apt.16179
PMID:33368517
Abstract
摘要

相似文献

1
Letter: propensity score-handle with care.信函：倾向评分——谨慎处理。
Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179.
2
Letter: propensity score-handle with care. Authors' reply.
Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.
3
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。
Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. doi: 10.1111/apt.15862.
4
Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.信函：优特克单抗用于治疗术后及难治性克罗恩病。
Aliment Pharmacol Ther. 2021 Apr;53(7):859-860. doi: 10.1111/apt.16281.
5
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
6
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
Aliment Pharmacol Ther. 2020 Oct;52(7):1253-1254. doi: 10.1111/apt.16009.
7
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1255-1256. doi: 10.1111/apt.16062.
8
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
Aliment Pharmacol Ther. 2020 Aug;52(4):751-752. doi: 10.1111/apt.15920.
9
Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
Aliment Pharmacol Ther. 2020 Aug;52(4):753-754. doi: 10.1111/apt.15959.
10
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.在 239 例对肿瘤坏死因子治疗抵抗的克罗恩病患者中，乌司奴单抗或维得利珠单抗的疗效。
Aliment Pharmacol Ther. 2020 May;51(10):948-957. doi: 10.1111/apt.15706. Epub 2020 Apr 6.

引用本文的文献

1
Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience.炎症性肠病生物药物的头对头比较：从随机对照试验到真实世界经验
Therap Adv Gastroenterol. 2021 May 3;14:17562848211010668. doi: 10.1177/17562848211010668. eCollection 2021.